Nov 2, 2016 by Brian Orelli, PhDWhy Cempra Inc. Got Crushed AgainThe biotech isn't having a good week.
Nov 2, 2016 by Brian Orelli, PhDAt IDEXX Laboratories, Inc., Margin Growth Is an Investor's Best FriendThe animal-diagnostics company continues to grow earnings through expanded margins.
Nov 2, 2016 by Brian Orelli, PhDWhy Myriad Genetics, Inc. Got Knocked Down TodayEarnings at the genetic-test maker fall short of expectations.
Nov 1, 2016 by Brian Orelli, PhDNovo Nordisk A/S Plans to Innovate and Diversify to Avoid Payer PressureThe diabetes specialist has had a rocky 2016 and it doesn't look any easier going forward, but innovation and diversification should help.
Nov 1, 2016 by Brian Orelli, PhDImmunoGen, Inc. Waits for DataInvestors eagerly await data from the biotech's phase 3 trial, but there will be some earlier-stage data in the interim.
Oct 31, 2016 by Brian Orelli, PhD5 Years After Adcetris Approval, Seattle Genetics, Inc. Still Focused on PipelineModest sales of Adcetris could accelerate if the biotech can get a first-line indication.
Oct 31, 2016 by Brian Orelli, PhDBioMarin Pharmaceutical Inc.: Sales Up, Losses Down, Waiting on PipelineThe biotech moves down the road towards profitability.
Oct 28, 2016 by Brian Orelli, PhDWhy Cempra Inc Got Crushed TodayA manufacturing delay has investors reassessing the biotech's current value.
Oct 28, 2016 by Brian Orelli, PhDWhy Novo Nordisk A/S Got Crushed TodayThe diabetes specialist cuts short- and long-term growth outlooks.
Oct 28, 2016 by Brian Orelli, PhDCelgene Corporation Is Firing on All CylindersThe biotech posts another great quarter and raises 2016 guidance.
Oct 27, 2016 by Brian Orelli, PhDBiogen Inc. Working With What It's Got as It Looks to DiversifyA lackluster multiple sclerosis market highlights the biotech's need to launch into other markets.
Oct 27, 2016 by Brian Orelli, PhDVertex Pharmaceuticals Incorporated Pushes Forward With Drug Combinations (and Reports Earnings, Too)Pipeline progress trumps the biotech's earnings report.
Oct 26, 2016 by Brian Orelli, PhDBaxter International Inc Gets More EfficientDespite tepid growth, the hospital supply company is growing its bottom line.
Oct 26, 2016 by Brian Orelli, PhDWhy Edwards Lifesciences Corp Got Crushed by Investors TodayA solid earnings report wasn't enough for investors with high expectations for the company's transcatheter heart valves.
Oct 25, 2016 by Brian Orelli, PhDWhy Waters Corporation Reported Lower TodayShares of the scientific-instrument manufacturer sank after an earnings report that forecast rocky waters ahead.
Oct 21, 2016 by Brian Orelli, PhDWhy Alkermes PLC Skyrocketed TodayPositive phase 3 data from the biotech's depression drug sends shares skyward.
Oct 20, 2016 by Brian Orelli, PhDNatus Medical Inc.: This BABY Keeps Chugging Along The hearing and neurology specialist makes up for tepid revenue with a nice quarterly earnings and guidance for the rest of the year.
Oct 20, 2016 by Brian Orelli, PhDWhy Rigel Pharmaceuticals, Inc. Got Hammered TodayA failed late-stage clinical trial sends the biotech's shares falling.
Oct 19, 2016 by Brian Orelli, PhDWhy Corbus Pharmaceuticals Holdings Inc Jumped Higher TodayThe biotech's CEO is scheduled to be on "Mad Money" ahead of a data release later this year.
Oct 19, 2016 by Brian Orelli, PhDWhy Acadia Healthcare Company Inc. Reported Lower TodayIgnore the press release headline. The problem is with a preliminary earnings report.
